Tr1X is pioneering the development of allogeneic engineered Tr1 Treg cell therapies aimed at treating autoimmune and inflammatory diseases, particularly focusing on conditions like treatment-refractory Crohn’s disease. Their approach leverages the unique properties of Tr1 cells, which are naturally occurring regulatory T cells that play a crucial role in maintaining immune homeostasis. By mimicking the function of these cells, Tr1X's therapies are designed to suppress unwanted immune activity while promoting the production of antigen-specific Tr1 cells. This dual action helps reset the immune system and restore balance, potentially transforming the treatment landscape for patients suffering from severe autoimmune conditions.

The company employs advanced genetic engineering techniques combined with extensive research in T cell biology to create scalable and effective cellular therapies. Tr1X's products are characterized by their ability to produce suppressive cytokines in localized microenvironments, ensuring targeted immune suppression without compromising protective immune responses. Additionally, these engineered cells demonstrate high stability and longevity, even in inflammatory settings, and possess the capability to migrate to sites of inflammation, where they can modulate effector cell responses and induce the formation of new Tr1 cells. This innovative approach positions Tr1X at the forefront of cellular therapy for immune diseases, with a commitment to improving patient outcomes through breakthrough scientific advancements.

United States

Tr1X Inc. (pr. "Trix")  is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.

Tr1X

Company Details